Q: Tell us about Data4Cure.

 

A: Data4Cure develops and provides its partners with an integrative platform that combines systems biology, machine learning and AI technologies to turn vast amounts of omics, phenotypic and clinical data (both public and proprietary) into a data-driven biomedical knowledge graph. The platform uses this information to build comprehensive maps of diseases to identify new drug targets and biomarkers, find new indications for existing drugs, and match drugs to patient subtypes. We are proud to work with some of the largest and most innovative pharmaceutical companies and leading research institutions who use our platform to gain new insights from their data and build their internal knowledge networks.

Q: What led you to found Data4Cure?

 

A: As a computer scientist and computational biologist, I am always interested in how we can combine and model different types of data together to better understand complex systems and make better decisions. Around 2013, I was working at UC San Diego, developing and publishing on new network and systems approaches which worked well for simple organisms such as yeast but weren’t yet as effective for human disease. I thought we can do better by bringing in a lot more diverse types of data and merging systems biology with some of the new machine learning and semantic learning technologies that were becoming available. That would require a new set of tools and a computational platform that would start to tie all of the pieces together. I thought the work could be more effective done through a company. So instead of looking to start my own academic lab, I left to start Data4Cure helped by our scientific co-founder Dr. Trey Ideker, key scientific advisors Drs. Lee Hood and Napoleone Ferrara, as well as early investors. We were very fortunate to be joined by extraordinary computational biologists and engineers and began working with pharmaceutical companies to apply some of the integrative systems biology machinery toward patient stratification and drug development. It gave us a good view into the problems people are facing both in terms of specific analytical challenges, as well as the bigger problem of growing knowledge from more and more data.

What we were able to develop over the last three to four years is an integrated system that not only applies many advanced analytical methods to the data but provides a technology platform to iteratively update knowledge based on new data and literature. The resulting information is stored in a dynamic data-driven knowledge graph that is unique to each organization. This technology became the basis for the Biomedical Intelligence Cloud — our SaaS offering for pharmaceutical R&D which we launched last year. We are continuously improving it by curating and feeding in new large datasets and building new applications to address a wider range of analytical problems.

Q: What are some of the key unique ideas behind the Biomedical Intelligence Cloud? What contextual knowledge do you bring in?

 

A: The key idea is convergence of evidence and information coming from multiple sources like multidimensional omics data, phenotypic data, molecular networks and pathways, literature, clinical trials, and other structured and non-structured data that may exist both within the organization and outside in the public domain. Typically information coming from each one of these sources is noisy, incomplete, and difficult to interpret. By putting the data together in context we are able to extract the most robust pieces of information and make better sense of it.

The Biomedical Intelligence Cloud uses a proprietary knowledge graph technology called CURIE to continuously aggregate various pieces of evidence, learn how they fit together and apply them toward interesting problems in the pharmaceutical and clinical R&D. We think of it also as convergence of systems biology and ML/AI because the technology leverages recent methods from machine learning and AI but is also heavily informed by the developments in systems biology and incorporates a lot of prior knowledge from the biomedical domain.

Q: What types of problems in pharmaceutical R&D do you help address and how does systems biology and ML help?

 

A: The platform has applications throughout the drug development pipeline from early target discovery and validation, to mechanism of action and efficacy studies, to patient selection and developing companion diagnostics. In each of these areas there is an opportunity for integrative systems-based modeling but there are also unique challenges. The platform helps address these individual areas using a set of dedicated applications.

For instance, to support target discovery and validation, users might start by building integrative molecular maps of diseases which integrate omics, phenotypic and literature information with molecular networks and pathways to identify the key system components with potential for therapeutic intervention. Precision medicine is all about precisely mapping disease subtypes and predicting how they might respond to therapy either as single agent or as combinations. This is where some of the other applications become useful. We have an application that performs a deep molecular subtyping of disease based on multidimensional omics data and specific disease pathways perturbed in each patient. Other applications couple machine learning algorithms with knowledge of molecular networks and pathways to predict sensitivity or resistance to drugs in specific patient subsets. We currently have over 10 applications available on the platform and are expanding with new ones in the next months.

Q: You will be speaking in the Immunotherapy Track as well as the AI showcase at PMWC 2018. What are the applications of the platform toward immune oncology? Can you give some use case examples of cancer biomarkers that the Biomedical Intelligence Cloud helped discover?

 

A: Immuno-oncology research and clinical trials is one the areas in which our platform has seen the most growth in 2017. We are particularly interested in understanding and predicting which patients across different histologies will respond to specific types of immunotherapy (e.g. PD1 or PD-L1 inhibitors) and which other patients may respond to combination therapies in which IO drugs might be combined with other therapies.

The power of the platform is that we can effectively combine multiple types of data, such as are often generated by the new IO clinical trials and apply a range of systems and ML approaches to make sense of these data. What is emerging is a view of the tumor-immune system interactions in which multiple factors such as cancer subtypes, immune infiltration, neoantigen load, checkpoint expression and tumor clonal evolution each may together determine response.

Our system can extract multidimensional information about disease biology coming from the analysis of large research cohorts and use it to boost signal and increase the ability to make accurate predictions for new clinical trial cohorts. In my talk I plan to discuss several case studies using recent trials in lung adenocarcinoma and melanoma.

We are very excited to contribute to the PMWC 2018 program. We’ve been part of the conference since the very beginning of Data4Cure. Every year the quality of the program and level of participants makes it a phenomenal event for anyone working in the field. The 2018 edition will be particularly interesting for anyone interested in immuno-oncology, and applications of machine learning and AI in medicine.

Late breaking: Dawn Barry leaves Illumina to lead Luna DNA -Blockchain Disrupting Healthcare Industry

“Every individual holds a valuable piece of the puzzle to understand disease and health, and researchers are all in need of more data. Discovery is hindered by putting the majority of data into small silos. Breaking down data silos and bringing individuals together will more quickly aggregate enough samples to rise above the complexity of genomics and identify disease candidates.” – Dawn Barry, President and Co-Founder, Luna DNA

Read More

Interview Dawn Barry the new President and Co-founder of Luna DNA

Q: In a sentence, what is Luna DNA going to do?

Read More

JPM18: Edico Genome, Illumina, Invitae, Regeneron, Thermo Fisher Scientific,… and the list goes on

It’s been an announcement-packed JPMorgan Healthcare Conference in San Francisco this week!

Read More

At PMWC 2018 Silicon Valley CMS Administrator Seema Verma Discusses the Future of Health Care

Genomics-based testing or new immunotherapies that revolutionize cancer care are changing how we approach disease…

Read More

Interview with Dr. Frank Lee, Global Healthcare & Life Sciences Industry Leader at IBM; Chief Architect, IBM Reference Architecture for Genomics – Speaker at PMWC 2018 Silicon Valley

Q: As a pioneer in high performance architectures for genomic research what are the biggest challenges that you see clients dealing with as they invest in precision medicine initiatives?

Read More

Q&A with Ira Mellman, PhD, Vice President, Cancer Immunology, Genentech – Speaker at PMWC 2018 Silicon Valley

Q: Immunotherapy is considered a huge game-changer and holds a lot of promises. Is the hype around immunotherapy justified? What are some of the exciting developments in the recent years?

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

Read More

Q&A with Matthew Kane, Co-founder & CEO, Precision BioSciences – Speaker at PMWC 2018 Silicon Valley

Q: What are the benefits of the Precision BioSciences’ ARCUS genome editing platform and what makes it unique?

Read More

Q&A with Jon Heimer, CEO, Olink Proteomics – Speaker at PMWC 2018 Silicon Valley

Q: Olink has been rapidly growing its’ library of human protein biomarker assays. What are the popular clinical applications for your biomarker panels?

Read More

2017 Review: A Clear Paradigm Shift from a one-size-fits-all model to personalized healthcare

2017 saw technology innovations, new therapies and diagnostics, value-based healthcare, and clinical protocol advancements as huge drivers, moving the needle…

Read More

Q&A with Peter Donnelly, Director, Wellcome Trust Centre for Human Genetics (Oxford) – Speaker at PMWC 2018 Silicon Valley

Q: How will genomics transform healthcare and how will it impact medicine? Beyond genetics and genomics what other data is relevant and why?

Read More

PMWC Interview with Janusz Dutkowski, Ph.D., Co-founder & CEO, Data4Cure – Speaker at PMWC 2018 Silicon Valley

Q: What are some of the key unique ideas behind the Biomedical Intelligence Cloud? What contextual knowledge do you bring in?

Read More

Q&A with Bob Terbrueggen, President & CEO, DxTerity – Speaker at PMWC 2018 Silicon Valley

Q: What are the challenges that the field of genomic research will face in the next five years?

Read More

Q&A with Mark Kiel, CSO and Co-founder, Genomenon – Speaker at PMWC 2018 Silicon Valley

Q: What are the challenges facing clinical interpretation of NGS data today?

Read More

Precision Medicine Jan 22-24th – learn from the experts at PMWC Silicon Valley 2018

Genomic Data Analysis / Next-Gen Sequencing, Immunotherapy / Cancer Care, & Artificial Intelligence / Machine Learning are all extensively covered at the conference, January 22-24

Read More
University of Michigan

About us:
The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

    • More than 70 sessions with 350+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Four tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Immuno-oncology
    • Cancer and rare disease diagnostics
    • Biomarker and companion diagnostics
    • Big data approaches
    • NGS applications
    • AI and machine learning applications
    • Advancements in liquid biopsy applications
    • Wellness & Aging
    • CRISPR
    • The human microbiome
    • Infectious disease ID and monitoring
    • The importance of patient engagement
    • 3-D technologies
    • Updates on data and regulatory policies
    • Metabolomics in precision medicine
    • mHealth and Telehealth

About us:
The Precision Medicine World Conference (PMWC), in its 13th installment, will take place in Silicon Valley on January 22-24, 2018. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

Agenda highlights:

    • More than 70 sessions with 350+ thought-provoking, insightful talks that cover all facets of precision medicine
    • Four tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
        • Immuno-oncology
        • Cancer and rare disease diagnostics
        • Biomarker and companion diagnostics
        • Big data approaches
        • NGS applications
        • AI and machine learning applications
        • Advancements in liquid biopsy applications
        • Wellness & Aging
        • CRISPR
        • The human microbiome
        • Infectious disease identification and monitoring
        • The importance of patient engagement
        • 3-D technologies
        • Updates on data and regulatory policies
        • Metabolomics in precision medicine
        • mHealth and Telehealth

One track will be dedicated to the various aspects of the All of Us Research Program, while another session will focus on educating California’s legislators.

 

Confirmed thought leaders include:

Sir John Bell

Sir John Bell

Regius Professor of Medicine, Oxford University

sally-davies

Dame Sally Davies

Chief Medical Officer, Department of Health, UK Government

BLA00002-Elizabeth-Blackburn

Elizabeth Blackburn

Nobel Laureate, President, Salk Institute for Biological Studies

George-Sledge

George Sledge

Professor, Division Chief, Stanford University Medical Center

Jeffrey Bluestone

Jeffrey Bluestone

CEO and President, Parker Institute for Cancer Immunotherapy

Christopher Ianelli

Christopher Ianelli

Founder and Chief Executive Officer,  iSpecimen

Kenneth J. Pienta

Kenneth J. Pienta

Director, Brady Urological Institute, Johns Hopkins Medicine

Roy Beveridge

Roy Beveridge

Senior Vice President & Chief Medical Officer, Humana

Kimberly Blackwell

Kimberly Blackwell

Professor of Medicine, Assistant Prof. of Radiation Oncology, Duke Cancer Institute

Joshua Denny

Joshua Denny

Professor of Biomedical Informatics & Medicine, Vanderbilt University Medical Center

Edward S. Kim

Edward S. Kim

Chair, Solid Tumor and Investigational Therapeutics, Levine Cancer Institute

Howard L. McLeod

Howard L. McLeod

Medical Director, Personalized Medicine Institute, Moffitt Cancer Center

Lee Newcomer

Lee Newcomer

SVP, UnitedHealthcare Oncology and Genetics

Vinod Khosla

Vinod Khosla

Partner and Founder of Khosla Ventures

Troy Brennan

Troy Brennan

Executive VP & CMO, CVS Health

Ira Mellman

Ira Mellman

VP, Cancer Immunology, Genentech

Event Highlights

When
January 22, 2018 8:00am to January 24, 2018 5:00pm
Where
Computer History Museum
1401 N Shoreline Blvd
Mountain View, CA 94043
Cost
$1850 by January 19th, 2018
Registration
3-Day Access to Talks, Exhibition & Reception:
See Registration Details

Registration: PMWC Conferences

Silicon Valley Jan 22-24, 2018

65+ Sessions 4 Tracks
350+ Speaker lineup
Access to the exhibition
Breakfast & lunch refreshments
Networking App
Award Reception

Having Trouble Registering? We accept all major credit cards. Select 'PayPal Check out' and press 'Pay with Debit or Credit Card'.
Click here or call (650)-961-8877 to contact the PMWC Team for Help.